Alessandro Chiesi, president of the Parma-based multinational, emphasizes the importance of innovation in the pharmaceutical sector, highlighting a record €723 million investment in R&D, which represents 23.8% of turnover. Despite Italy's leadership in pharmaceuticals, he calls for systemic changes to enhance collaboration between universities and the private sector, aiming to boost healthcare R&D investments. The newly inaugurated Biotech Center of Excellence in Parma aims to advance the development of biologic drugs, particularly for rare diseases, showcasing the company's commitment to addressing social challenges alongside business opportunities.
